To date, nature has been the best teacher for drug discovery scientists, especially for those who develop antimicrobial drugs. Lately, a new example proving this notion emerged in press - a recent publication in a prestigious research journal Nature describing a new powerful method of identifying yet unknown classes of antibiotics by learning from bacteria living in our body - microbiota.
Understanding and controlling inflammation processes has become a central goal in modern medical research. A number of companies developing novel anti-inflammatory drugs has emerged to grow on the wave of recent research findings.
Integrins are a group of transmembrane receptors playing a major role in cell-cell and cell-extracellular matrix (ECM) interactions. When triggered, integrin receptors transduce signals to the interior of the cell, providing quick and flexible “status update” about chemical composition and mechanical status of the ECM. It results in a cellular response, such as a change in the cell shape, regulation of the cell cycle, adjusting motility, or adding new receptors to the cell membrane.
A billionaire Sean Parker, known as a founder of Facebook and Napster, has steeply entered Life Sciences industry to fund the world’s first-ever CRISPR/Cas9 trial, backed by US federal authorities. Upon success, the probability of which is now hard to assess, this technology can revolutionize the way cancer and many other diseases are treated. This time, Sean Parker is playing a bigger game than ever, however, uncertainty is huge.